SRZN
What one share of Surrozen, Inc./DE holds
Biological Products, (No Diagnostic Substances)
We are a biotechnology company committed to discovering and developing product candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair. Our current strategic focus is ophthalmology, where Wnt signaling plays a central role in retinal vascular integrity, barrier function, and tissue maintenance.
Surrozen, Inc./DE’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.14 |
|---|---|
| Profit | −$32.94 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$3.47 |
| Cash and investments | $8.68 |
| Book value | −$18.60 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$30.72 | $0.82 | −$28.15 | — | $38.86 |
| 2021 | $0.00 | −$33.20 | $0.77 | −$30.43 | — | $46.97 |
| 2022 | $5.40 | −$15.56 | $0.31 | −$19.39 | — | $37.89 |
| 2023 | $0.00 | −$21.33 | $0.20 | −$20.20 | — | $18.39 |
| 2024 | $3.63 | −$21.67 | $0.01 | −$6.02 | — | −$6.55 |
| 2025 | $0.47 | −$32.37 | $0.02 | −$4.06 | — | −$19.21 |